

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<i>Complete if Known</i>	
				Application Number	10/590,445 – Conf. # 6734
				Filing Date	August 24, 2006
				First Named Inventor	Michael Jung
				Art Unit	1614
				Examiner Name	James D. Anderson
Sheet	3	of	7	Attorney Docket Number	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>					

C10	Keown et al., <u>Methods in Enzymology</u> , 185:527-537 (1990).	
C11	Mansour et al., <u>Nature</u> , 336:348-352 (1988).	
C12	Muller et al., 1991, <u>Mol. & Cell. Bio.</u> 11:1785.	
C13	Urlaub et al., <u>Proc. Natl. Acad. Sci. USA</u> , 77:4216 (1980).	
C14	Stinchcomb et al., <u>Nature</u> , 282:39 (1979).	
C15	Kingsman et al., <u>Gene</u> , 7: 141 (1979).	
C16	Tschumper et al., <u>Gene</u> , 10: 157 (1980).	
C17	Jones, <u>Genetics</u> , 85:23 (1977).	
C18	Feldman, B.J. & Feldman, D. The development of androgen-independent prostate cancer. <u>Nat Rev Cancer</u> 1, 34-45 (2001).	
C19	Gelmann, E.P. Molecular biology of the androgen receptor. <u>J Clin Oncol</u> 20, 3001-15 (2002).	
C20	Balk, S.P. Androgen receptor as a target in androgen-independent prostate cancer. <u>Urology</u> 60, 132-8; discussion 138-9 (2002).	
C21	Taplin, M.E. et al. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. <u>Cancer Res</u> 59, 2511-5 (1999).	
C22	Taplin, M.E. et al. Androgen receptor mutations in androgen-independent prostate cancer: <u>Cancer and Leukemia Group B Study</u> 9663. <u>J Clin Oncol</u> 21, 2673-8 (2003).	
C23	Visakorpi, T. et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. <u>Nat Genet</u> 9, 401-6 (1995).	
C24	Taplin, M.E. et al. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. <u>N Engl J Med</u> 332, 1393-8 (1995).	
C25	Veldscholte, J. et al. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. <u>Biochem Biophys Res Commun</u> 173, 534-40 (1990).	
C26	Matias, P.M. et al. Structural basis for the glucocorticoid response in a mutant human androgen receptor (AR(ccr)) derived from an androgen-independent prostate cancer. <u>J Med Chem</u> 45, 1439-46 (2002).	
C27	Craft, N., Shostak, Y., Carey, M. & Sawyers, C.L. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. <u>Nat Med</u> 5, 280-5 (1999).	
C28	Gioeli, D. et al. Androgen receptor phosphorylation. Regulation and identification of the phosphorylation sites. <u>J Biol Chem</u> 277, 29304-14 (2002).	
C29	Kato, S. et al. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. <u>Science</u> 270, 1491-4 (1995).	
C30	Font de Mora, J. & Brown, M. AIB1 is a conduit for kinase-mediated growth factor signaling to the estrogen receptor. <u>Mol Cell Biol</u> 20, 5041-7 (2000).	
C31	Tremblay, A., Tremblay, G.B., Labrie, F. & Giguere, V. Ligand-independent recruitment of SRC-1 to estrogen receptor beta through phosphorylation of activation function AF-1. <u>Mol Cell</u> 3, 513-9 (1999).	

Examiner Signature	Date Considered
--------------------	-----------------